New understanding and research progression for triplenegative breast cancer

doi:10.3760/cma.j.issn.1673-422X.2013.11.014

摘要/Abstract

摘要： 三阴性乳腺癌（TNBC）呈高度异质性，具有独特的危险因素、分子生物学特点、临床表现及预后。TNBC术后易复发且复发后生存率低、治疗方式少。化疗仍然是目前TNBC患者的主要治疗方式。为了提高TNBC疗效，需要不断地寻找新的分子预测标志物及新的药物靶点。

关键词: 乳腺肿瘤, 药物疗法, 三阴性

Abstract: Triplenegative breast cancer (TNBC) is a heterogeneous disease. It has distinct risk factors, molecular biology features, clinical presentations and prognosis. TNBC recurrence is common after resection, and the survival rate is low and available treatment options are few after recurrence. To date, chemotherapy is the main treatment strategy for TNBC. There is a great need for new molecular predictive marks and drug targets for improving the efficacy of TNBC treatment.

Key words: Breast neoplasms, Drug therapy, Triple negative

王新昭, 左文述, 于志勇 . [J]. 国际肿瘤学杂志, 2013, 40(11): 846-849.

WANG Xin-Zhao, ZUO Wen-Shu, YU Zhi-Yong. New understanding and research progression for triplenegative breast cancer[J]. Journal of International Oncology, 2013, 40(11): 846-849.

参考文献

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics.CA Cancer J Clin，2011,61(2):69-90. ［2］ Cheang MC, Voduc D, Bajdik C, et al. Basallike breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res, 2008, 14(5):1368-1376. ［3］ Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist, 2010, 15(Suppl 5):39-48. ［4］ de Ronde JJ, Hannemann J, Halfwerk H, et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat, 2010, 119(1):119-126. ［5］ Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat, 2009, 113(2):357-370. ［6］ Perez CA, Zumsteg ZS, Gupta G, et al. Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis. Breast cancer research and treatment, 2013, 139(2):497-506. ［7］ Evans DG, Howell A. Are we ready for online tools in decision making for BRCA1/2 mutation carriers?. J Clin Oncol, 2012, 30(5):471-473. ［8］ Wang Y, Ikeda DM, Narasimhan B, et al. Estrogen receptor negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology, 2008, 246(2):367-375. ［9］ Thike AA, Cheok PY, Jara-Lazaro AR, et al. Triplenegative breast cancer: clinicopathological characteristics and relationship with basallike breast cancer. Mod Pathol, 2010,23(1):123133. ［10］ Persson M, Andrén Y, Mark J, et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA, 2009,106(44):1874018744. ［11］ Jatoi I, Anderson WF, Jeong JH, et al. Breast cancer adjuvant therapy: time to consider its time-ependent effects. J Clin Oncol, 2011, 29(17):2301-2304. ［12］ Lowery AJ, Kell MR, Glynn RW, et al. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat, 2012, 133(3):831-841. ［13］ Aleskandarany MA, Green AR, Benhasouna AA, et al. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res, 2012, 14(1):R3. ［14］ Cancello G, Maisonneuve P, Rotmensz N, et al. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat, 2011, 127(3):713-720. ［15］ Tang D, Xu S, Zhang Q, et al. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol, 2012, 29(2):526-533. ［16］ Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res, 2010, 12(5):R68. ［17］ von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant che-motherapy in various intrinsic breast cancer subtypes. J Clin Oncol, 2012, 30(15):1796-1804. ［18］ Zumsteg ZS, Morrow M, Arnold B, et al. Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T_1-2N₀ Triple-Negative Breast Cancer. An Surg Oncol, 2013, 20(11):3469-3476. ［19］ Metzger-Filho O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triplenegative breast cancer. J Clin Oncol, 2012, 30(15):1879-1887. ［20］ Ignatov T, Poehlmann A, Ignatov A, et al. BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC. Breast Cancer Res Treat, 2013, 141(2):205-212. ［21］ Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triplenegative) breast cancer. Breast Cancer Res Treat, 2010, 121(2):261-271. ［22］ Erten C, Demir L, Somali I, et al. Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients?. Asian Pac J Cancer Prev, 2013, 14(6):3711-3717. ［23］ Miles DW, Chan A, Dirix LY, et al. Phase Ⅲ study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol, 2010, 28(20):3239-3247. ［24］ Brufsky A, Valero V, Tiangco B, et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat, 2012, 133(3):1067-1075. ［25］ Yadav S, Sehrawat A, Eroglu Z, et al. Role of SMC1 in overcoming drug resistance in triple negative breast cancer. PloS one, 2013, 8(5):e64338.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[4]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[5]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[6]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[7]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[8]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[9]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[10]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[11]	潘书兰, 刘畅, 贺平. 福瑞替尼对三阴性乳腺癌血管生成、肿瘤生长及IRE1-ASK1-JNK通路的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 457-462.
[12]	徐凡, 王婧, 毛宁, 王世雄, 李金茂. 戈沙妥珠单抗治疗晚期三阴性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 508-510.
[13]	李晨曦, 赵宏伟. 二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[14]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[15]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.